Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;210(1):46-53.
doi: 10.1097/JU.0000000000003491. Epub 2023 Apr 25.

Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening

John T Wei  1 , Daniel Barocas  2 , Sigrid Carlsson  3 , Fergus Coakley  4 , Scott Eggener  5 , Ruth Etzioni  6 , Samson W Fine  3 , Misop Han  7 , Sennett K Kim  8 , Erin Kirkby  8 , Badrinath R Konety  9 , Martin Miner  10 , Kelvin Moses  2 , Merel G Nissenberg  11 , Peter A Pinto  12 , Simpa S Salami  1 , Lesley Souter  13 , Ian M Thompson  14 , Daniel W Lin  15
Affiliations

Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening

John T Wei et al. J Urol. 2023 Jul.

Erratum in

Abstract

Purpose: The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy, and follow-up. This is Part I of a two-part series that focuses on prostate cancer screening. Please refer to Part II for discussion of initial and repeat biopsies as well as biopsy technique.

Materials and methods: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane Database of Systematic Reviews (January 1, 2000-November 21, 2022). Searches were supplemented by reviewing reference lists of relevant articles.

Results: The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsy, and biopsy technique.

Conclusions: Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening intervals and tailored screening, and the use of available online risk calculators is encouraged.

Keywords: DRE; PSA; biopsy; early detection of prostate cancer; imaging; prostate cancer; prostate cancer screening; risk calculator; screening interval; shared decision-making.

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
INITIAL SCREENING FOR PROSTATE CANCER
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Wagle NS et al.: Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17. - PubMed
    1. Rawla P: Epidemiology of prostate cancer. World J Oncol 2019; 10: 63. - PMC - PubMed
    1. Eggener SE, Scardino PT, Walsh PC et al.: Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869. - PMC - PubMed
    1. Mahal BA, Berman RA, Taplin ME et al.: Prostate cancer-specific mortality across gleason scores in black vs nonblack men. Jama 2018; 320: 2479. - PubMed
    1. Makarov DV, Chrouser K, Gore JL et al.: Aua white paper on implementation of shared decision making into urological practice. Urology Practice 2016; 3: 355. - PubMed

Substances